U.S., Nov. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07226661) titled 'Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder' on Nov. 07.
Brief Summary: This study will evaluate the efficacy and safety of SPN-821 in adults with major depressive disorder
Study Start Date: Jan. 01, 2026
Study Type: INTERVENTIONAL
Condition:
Major Depressive Disorder (MDD)
Intervention:
DRUG: SPN-821 2400 mg
SPN-821 is a novel, orally bioavailable, selective, direct enhancer of mTORC1 cellular signaling
DRUG: Placebo
Matched placebo oral tablets
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Supernus Pharmaceuticals, Inc.
Disclaimer: Curated by HT Syndication....